Psilocybin organ safety — liver, cardiovascular, and long-term physiological effects

The pharmacological safety profile is genuinely excellent. Psilocybin is not hepatotoxic — unlike MDMA, alcohol, and many pharmaceutical drugs, it does not produce liver enzyme elevations at clinical doses. Animal studies show no organ toxicity at doses far above anything used clinically. The LD50 (lethal dose) for psilocybin in animals is extremely high relative to active dose — you would need to consume an amount physiologically impossible to ingest. No human deaths from psilocybin toxicity have ever been documented.

Cardiovascular: psilocybin does increase heart rate and blood pressure during the acute session. For healthy adults this is not a significant concern. For those with hypertension or cardiovascular disease, it warrants medical evaluation before use. The increases are not dramatic — similar to mild-moderate exercise levels. Clinical trial participants with normal cardiovascular function are routinely monitored during sessions and no serious cardiac events have been reported in any published psilocybin trial.

Long-term human data: the observational epidemiology is reassuring. Studies of people with extensive lifetime psychedelic use (hundreds of experiences) show no evidence of organ damage, cognitive impairment, or increased disease risk compared to matched controls. The Krebs and Johansen (2013) study of 21,000+ psychedelic users in population data found no increased mental health problems, medical treatment, or any negative health outcome associated with lifetime psychedelic use.